Invivyd (IVVD) Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Go back to Invivyd (IVVD) Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

January 10, 2025 7:01 AM EST

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as susceptible to PEMGARDA) together constitute the majority of national SARS-CoV-2 variantsXEC data underscore continued pemivibart activity in the face of virus evolution including recently emerging types of structural changes to spike N-terminal domainData submitted to FDA, with timely update to PEMGARDA Fact Sheet for Healthcare Providers anticipatedContinued... More